Product Research
Paclitaxel
Docetaxel
Vinorelbine
Ifosfamide
Mesna
Pirarubicin
Aclarubicin
Adriamycin
Daunorubicin
Vincristine
Bleomycin
Lastet



 

Docetaxel is a kind of semisynthetic antitumor drug developed by Sanofi-Aventis Company (Rhone-Poulenc Rorer Company) of France. It is a kind of paclitaxel anti-tumor drugs and it can depress the cell division by freezing frameworks inner cell compacted by microtubule. In a cell cycle, microtubules get together and then disaggregate, and docetaxel can promote microtubules to get together but interrupt them to disaggregate. For this reason, it can stop a lot of tumor cells division and lead them to apoptosis.

The applicable symptoms of docetaxel using in China:
  1. Therapy for failed antephase chemotherapy late or metastatic breast cancer. only if it pertaining to clinical taboo. Ante-phase chemotherapy should include anthracene nucleus anti-tumor drugs.
  2. Therapy for DDP chemotherapy failed late or metastatic non-small cell lung cancer.
Besides, it is approved by FDA of America to apply to in the following situation:
  1. Curing operative and lymphoid nodes positive breast cancer when combining with adriamycin and cyclophosphamide (TAC program).
  2. curing part late or metastatic non-small cell lung cancer combining with DDP.
  3. Curing part late or metastatic non-small cell lung cancer only with itself.
  4. Curing non-androgen dependent metastatic carcinoma of prostate combining with dehydrocortisone.
  5. Curing late gastric cancer with DDP and 5-FU.

The experts co-operate association of docetaxel published "The multicentre and ran compare research into the prospective of Xicun (docetaxel injection)" *, we have drawn a conclusion: in curing breast cancer and non-small cell lung cancer, using Xicun only or combining with DDP program is safe and effective with good tolerance.The therapy effect or adverse effect is just similar to the import drug-Taxotere.

Docetaxel is a breed of "Catalogue of National Essential Drugs "and "Catalogue of National Essential Medical Insurance Drugs",and also lot basic medication in curing tumors.

* Hao Xuezhi, Zhang Xiangru, Sun Yan. Clinical co-operation group of Docetaxel. The clinical observe of national produced docetaxel in curing breast cancer and non-small cell lung cancer. Joural of China Clinic Tumor. 2005, 32 (18): 1064-1066.

 
  国家食品药品监督管理局世界卫生组织中国医学科学院深圳万维医药贸易有限公司  
  深圳万乐药业有限公司 版权所有
Copyright © 2004 Shenzhen Main Luck Phar maceuticals Inc. All right reserved
Email:wanle@wanle.com.cn
 
Home Site Map English Version